アフェレシス採取した末梢血幹細胞の性状

概要

論文の詳細を見る
Peripheral blood stem cells (PBSCs) has been widely used in lieu of bone marrow (BM) for both autografts and allografts in patients with malignancies or hematological diseases. It has been well known that hematopoietic stem cells are mobilized during the recovery phase following myelosuppresive chemotherapy upon administration of recombinant hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF), or after combined application of chemotherapy and hematopoietic growth factors. As mobilized CD 34^+ cells in PBSC express less c-kit and CD 71 but more HLA-DR and CD 38 than BM CD 34^+ cells, the majority of PBSC may be more mature progenitors. Although hematopoietic recovery is generally faster in PBSC transplantation (PBSCT) than in BM transplantation (BMT), there has been concern about the functional properties of PBSCs with respect to their long-term capabilities. On the other hand, in a recent report, peripheral blood CD 34^+ cells were more abundant in the G 1-phase, and significantly more responsive to hematopoietic growth factors such as interleukin-3 (IL-3) and stem cell factor (SCF) as compared to BM CD 34^+ cells. These results indicate that mobilized hematopoietic stem cells can be considered to possess both committed and immature hematopoietic progenitor cells as well as BM cells. A phenotypic analysis of hematopoietic progenitor cells has shown that BM and PBSCs have a variety of adhesive molecules. However, very late activation antigen-4 (VLA-4), leukocyte function antigen-1 (LFA-1), and SCF (c-kit ligand) are lower in PBSCs than BM cells. Down-modulation of adhesive molecules may contribute to the release of progenitor cells from BM. Although more lymphoid cells (T, B, and NK cells) are contained in PBSC than in BM, the incidence of acute graft versus host disease (GVHD) is not different between PBSCT and BMT. The mechanisms of not inducing severe GVHD are still unclear. Some investigators have reported that type 2 helper T cells (Th 2) might play a role in neative regulation for developing GVHD. It has also been reported that PBSCs including more lymphoid subsets might mediate graft versus-leukemia (GVL) effects without inducing severe GVHD. In conclusion. PBSCs are thought to be enough to reconstitute hematopoiesis arter myeloablative treatment have some good points in that they can bring faster hematopoietic recovery and have possible immunological anti-tumor effects.
日本アフェレシス学会の論文
1999-11-30

アフェレシス採取した末梢血幹細胞の性状

スポンサーリンク

概要

著者

関連論文

スポンサーリンク